HB Wealth Management LLC Buys Shares of 12,899 Takeda Pharmaceutical Co. $TAK

HB Wealth Management LLC purchased a new stake in shares of Takeda Pharmaceutical Co. (NYSE:TAK) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 12,899 shares of the company’s stock, valued at approximately $199,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. GAMMA Investing LLC boosted its position in Takeda Pharmaceutical by 22.6% during the 1st quarter. GAMMA Investing LLC now owns 7,042 shares of the company’s stock worth $105,000 after buying an additional 1,296 shares during the period. Allspring Global Investments Holdings LLC raised its stake in shares of Takeda Pharmaceutical by 5.4% during the first quarter. Allspring Global Investments Holdings LLC now owns 21,373 shares of the company’s stock valued at $319,000 after acquiring an additional 1,098 shares during the last quarter. Farther Finance Advisors LLC lifted its holdings in shares of Takeda Pharmaceutical by 29.2% during the first quarter. Farther Finance Advisors LLC now owns 4,620 shares of the company’s stock worth $69,000 after purchasing an additional 1,045 shares during the period. Vontobel Holding Ltd. bought a new stake in shares of Takeda Pharmaceutical in the first quarter worth $262,000. Finally, Park Avenue Securities LLC increased its holdings in Takeda Pharmaceutical by 15.1% in the first quarter. Park Avenue Securities LLC now owns 31,828 shares of the company’s stock valued at $473,000 after purchasing an additional 4,177 shares during the period. Institutional investors and hedge funds own 9.17% of the company’s stock.

Takeda Pharmaceutical Stock Down 0.6%

Shares of NYSE TAK opened at $14.47 on Wednesday. The company has a quick ratio of 0.59, a current ratio of 1.16 and a debt-to-equity ratio of 0.60. The company’s fifty day simple moving average is $14.85 and its 200 day simple moving average is $14.81. The firm has a market cap of $46.03 billion, a PE ratio of 48.22 and a beta of 0.21. Takeda Pharmaceutical Co. has a 12-month low of $12.80 and a 12-month high of $15.69.

Takeda Pharmaceutical (NYSE:TAK) last issued its earnings results on Wednesday, July 30th. The company reported $0.52 EPS for the quarter, beating analysts’ consensus estimates of $0.47 by $0.05. Takeda Pharmaceutical had a return on equity of 10.50% and a net margin of 3.20%.The business had revenue of $7.45 billion during the quarter, compared to analyst estimates of $7.96 billion. Takeda Pharmaceutical has set its FY 2025 guidance at 3.360-3.360 EPS. As a group, sell-side analysts forecast that Takeda Pharmaceutical Co. will post 1.64 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have commented on TAK shares. Zacks Research downgraded Takeda Pharmaceutical from a “hold” rating to a “strong sell” rating in a report on Thursday, August 21st. Weiss Ratings restated a “hold (c)” rating on shares of Takeda Pharmaceutical in a research report on Saturday, September 27th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold”.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.